315 related articles for article (PubMed ID: 24670538)
1. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Meng XY; Zhang Q; Li Q; Lin S; Li J
J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
[TBL] [Abstract][Full Text] [Related]
2. Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.
Šelemetjev S; Ðoric I; Paunovic I; Tatic S; Cvejic D
Am J Clin Pathol; 2016 Nov; 146(5):594-602. PubMed ID: 27806941
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
4. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.
Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM
J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590
[TBL] [Abstract][Full Text] [Related]
5. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
6. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M
Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738
[TBL] [Abstract][Full Text] [Related]
7. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
[TBL] [Abstract][Full Text] [Related]
8. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
Lin SY; Wang YY; Sheu WH
Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
[TBL] [Abstract][Full Text] [Related]
9. Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma.
Huang Y; Dong W; Li J; Zhang H; Shan Z; Teng W
BMC Cancer; 2014 May; 14():383. PubMed ID: 24884830
[TBL] [Abstract][Full Text] [Related]
10.
Stuchi LP; Castanhole-Nunes MMU; Maniezzo-Stuchi N; Biselli-Chicote PM; Henrique T; Padovani Neto JA; de-Santi Neto D; Girol AP; Pavarino EC; Goloni-Bertollo EM
Genes (Basel); 2020 Aug; 11(9):. PubMed ID: 32824922
[TBL] [Abstract][Full Text] [Related]
11. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
12. Expression of the NOB1 gene and its clinical significance in papillary thyroid carcinoma.
Lin S; Meng W; Zhang W; Liu J; Wang P; Xue S; Chen G
J Int Med Res; 2013 Jun; 41(3):568-72. PubMed ID: 23685895
[TBL] [Abstract][Full Text] [Related]
13. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
14. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma.
Qing W; Fang WY; Ye L; Shen LY; Zhang XF; Fei XC; Chen X; Wang WQ; Li XY; Xiao JC; Ning G
Thyroid; 2012 Sep; 22(9):905-10. PubMed ID: 22870901
[TBL] [Abstract][Full Text] [Related]
15. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
16. MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression.
Roncevic J; Djoric I; Selemetjev S; Jankovic J; Dencic TI; Bozic V; Cvejic D
Pathology; 2019 Jan; 51(1):55-61. PubMed ID: 30497805
[TBL] [Abstract][Full Text] [Related]
17. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
19. VEGF-C and COX-2 expression in papillary thyroid cancer.
Siironen P; Ristimäki A; Narko K; Nordling S; Louhimo J; Andersson S; Haapiainen R; Haglund C
Endocr Relat Cancer; 2006 Jun; 13(2):465-73. PubMed ID: 16728574
[TBL] [Abstract][Full Text] [Related]
20. RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.
Su X; He C; Ma J; Tang T; Zhang X; Ye Z; Long Y; Shao Q; Shao J; Yang A
PLoS One; 2016; 11(11):e0165596. PubMed ID: 27802347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
